Incyte price to free cash flow INCY

Market value divided by free cash flow over the last twelve months, since 2015.

Today, Oct 23, 2026: 12.2×
10-year median: 28.1×
Against its 10-year history: 1st; percentile: 0 is its lowest day, 100 its highest
10-year range: 11.9× to 492×
Peer median: 27.7×

Incyte's price to free cash flow is 12.2× as of Oct 23, 2026.

That is below its ten-year median of 28.1×, lower than on 99% of days in the last ten years.

Over that time it ranged from 11.9× in Oct 2026 to 492× in Sep 2017.

The median for 10 biotech stocks of a similar size is 27.7×.

Price to free cash flow over time

median 28.1×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	12.2×	11.9×	17.8×
2025	16.4×	15.3×	465×
2024	434×	15.1×	478×
2023	24.2×	16.5×	26.8×
2022	25.1×	22.3×	32.4×
2021	29.8×	26.2×	37.5×
2020	33.3×	22.9×	35.5×
2019	32.3×	30.6×	197×
2018	148×	139×	160×
2017	490×	121×	492×
2016	112×	85.5×	486×
2015	359×	312×	400×

Against its peers

Companies in Biotechnology nearest Incyte's size, closest first, today.

Company	Price to free cash flow
INCYIncyte	12.2×
UTHRUnited Therapeutics	23.1×
ALNYAlnylam Pharmaceuticals	37.8×
EXELExelixis	13.6×
NBIXNeurocrine Biosciences	16.7×
HALOHalozyme Therapeutics	17.7×
ONCBeOne Medicines	32.3×
TECHBIO-TECHNE	43.2×
RGENRepligen	89.2×
KRYSKrystal Biotech	35.8×
REGNRegeneron Pharmaceuticals	22.0×
Peer median	27.7×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Incyte

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.